Santen Pharmaceutical Company Description
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally.
Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; and ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2α derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H₁ receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis.
The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2α derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension.
In addition, it develops oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase III clinical trial for treatment of ptosis; and omidenepag isopropyl, an EP2 receptor agonist that is in phase III clinical trial for the treatment of glaucoma and ocular hypertension.
Further, the company offers atropine sulfate, a non-selective muscarinic antagonist that is in phase II/III clinical trials for the treatment of juvenile myopia; olodaterol hydrochloride, a β2 receptor agonist that has completed phase 1/2a clinical trial for the treatment of a dry eye; and sirolimus, an ophthalmic suspension which is in phase 2a clinical trial for the treatment of fuchs endothelial corneal dystrophy and meibomian gland dysfunction.
The company was founded in 1890 and is headquartered in Osaka, Japan.
| Country | Japan |
| Founded | 1890 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 3,849 |
| CEO | Takeshi Ito |
Contact Details
Address: Grand Front Osaka Tower A Osaka, 530-8552 Japan | |
| Phone | 81 6 7664 8621 |
| Website | santen.com |
Stock Details
| Ticker Symbol | SNPHY |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | US80287P1003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Takeshi Ito | President, Chief Executive Officer and Representative Director |
| Kazuo Koshiji | Chief Financial Officer and Corporate Officer |
| Rie Nakajima | Chief Operating Officer, Corporate Officer and Director |
| Daisuke Nakata | Chief Digital and Information Officer |
| Kaori Itagaki | General Manager of Investor Relations Group |
| Mika Masunari | General Counsel and Chief Compliance Officer |
| Shinichi Teramachi | Corporate Officer, Head of Sales and Head of Japan Sales and Marketing |
| Kenji Morishima | Corporate Officer and Head of China Product Development Department |
| Takahiro Morita | Global Head of Core Principle and Sustainability and Corporate Officer |
| Takeshi Matsugi | Head of Research & Development Strategic Operations |